Early local recurrence and one-year mortality of rectal cancer after restricting the neoadjuvant therapy regime. Issue 4 (April 2019)

• Record Type: Journal Article
• Authors: Tersteeg, Janneke J.C.; van Esch, Levi M.; Gobardhan, Paul D.; Kint, Peter A.M.; Rozema, Tom; Crolla, Rogier M.P.H.; Schreinemakers, Jennifer M.J.
• Is Part Of: European journal of surgical oncology. Volume 45:Issue 4(2019)
• Page Start: 597
• Page End: 605
• Publication Date: 2019-04
• Subjects: Rectal cancer -- Radiotherapy -- Local recurrence -- Mortality; Oncology -- Periodicals; Cancer -- Surgery -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- surgery -- Periodicals; Cancer -- Chirurgie -- Périodiques; Cancérologie -- Périodiques; Oncologie; Chirurgie (geneeskunde); Electronic journals; Electronic journals -- Sciences; Electronic journals -- Medicine; Electronic journals; 616.994059005
• DOI: 10.1016/j.ejso.2018.12.006
• Languages: English
• ISSNs: 0748-7983

Abstract

Abstract: Introduction: To reduce the risk of local recurrence after rectal cancer surgery, neoadjuvant radiotherapy (RT) can be applied. However, as this causes morbidity and increases mortality, new Dutch guidelines withhold RT in low-risk patients. The aim of this study is to investigate if early local recurrence and one-year mortality in rectal cancer patients has changed since this more restricting indication for neoadjuvant RT was introduced in 2014. Methods: This retrospective study included all consecutive patients treated with a mesorectal excision for primary rectal cancer in the Amphia Hospital, the Netherlands, between January 2011 and July 2016. Data were extracted from the electronic patient records. Survival data were collected from the Municipal Personal Records Database. Results: Between 2011 and July 2016, 407 resections of primary rectal cancer without synchronic metastases were performed, 225 under the old guidelines and 182 under the new guidelines. Significantly fewer patients received neoadjuvant treatment under the new guidelines (89% vs 41%, p < 0.001). Both clinical tumour stage (p = 0.001) and clinical lymph node stage (p < 0.001) were lower in the new group, but no difference in pathologic TN-stage was found. There was no difference in one-year local recurrence (2.2% in both groups, p = 0.987), nor in one-year mortality (5.3% vs 3.8%, p = 0.479). Conclusion: Introducing a new guideline and thereby restricting the indication for neoadjuvant RT in rectal cancer patients did not increase the early local recurrence rate or decreased one-year mortality in our hospital.